SION is a binary event stock tied to Phase 2a SION-719 proof-of-concept data expected summer 2026. The completion of enrollment de-risks the timeline but provides no efficacy signal. Traders should monitor for sweat chloride data as the primary efficacy readout — positive results could drive significant upside given the large CF market opportunity, while negative results would likely be devastating for the stock. The $289.9M cash runway into 2028 provides ample time for multiple catalysts.
Price Chart
Executive Summary
Sionna Therapeutics reported Q1 2026 financial results with a net loss of $26.8M ($-0.60/share), wider than the $16.5M loss in Q1 2025, as R&D and G&A expenses increased to support pipeline advancement. The key catalysts are the completion of enrollment in the Phase 2a trial of SION-719 and the ongoing Phase 1 dual combination trial of SION-451, both on track for topline data in summer 2026. Cash position of $289.9M is expected to fund operations into 2028, but the lack of revenue and widening losses make this a neutral operational update with binary event risk tied to upcoming clinical readouts.
Key Financial Metrics
Key Facts
- Net loss of $26.8M for Q1 2026 vs $16.5M in Q1 2025, driven by increased R&D ($19.0M vs $13.7M) and G&A ($10.6M vs $6.0M) expenses
- Cash, cash equivalents, and marketable securities of $289.9M as of March 31, 2026, down from $310.3M at year-end 2025
- Enrollment completed in PreciSION CF Phase 2a proof-of-concept trial of SION-719; topline data expected summer 2026
- Phase 1 dual combination trial of SION-451 with SION-2222 and SION-109 also on track for summer 2026 topline data
- Encore data from prior NACFC presentations to be featured at ECFS conference June 3-6, 2026
- No revenue generated; company is a clinical-stage biopharmaceutical with no approved products
Financial Impact
Net loss increased $10.3M year-over-year to $26.8M; cash burn of $20.4M in Q1 2026
Risk Factors
- Phase 2a trial failure or underwhelming efficacy data would severely impair stock value
- Cash burn rate increasing as trials advance; no revenue to offset expenses
- Competition from Vertex Pharmaceuticals' established CFTR modulator therapies
- Dilution risk from future capital raises to fund ongoing trials and operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033870 |
| Document: sion-20260512.htm | 0001628280-26-033870 |
| Document: 0001628280-26-033870-index-headers.html | 0001628280-26-033870 |
| Document: 0001628280-26-033870-index.html | 0001628280-26-033870 |
| Document: 0001628280-26-033870.txt | 0001628280-26-033870 |
| 8-K Data (Synthetic) | 0001628280-26-033870 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $4.50 $7.30 | ▼ −62.22% | ▼ −63.14% | $5.04 (−12.00%) |
Aug 6, 2026 8w ago | 8-K | $49.61 $6.75 | ▼ −86.39% | ▼ −86.99% | $5.04 (−89.84%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▲ +12.70% | ▲ +10.27% | $5.04 (−88.87%) |
Jul 9, 2026 12w ago | Insider Cluster | $45.29 $51.04 | ▼ −12.70% | ▼ −10.27% | $5.04 (+88.87%) |
Jul 7, 2026 12w ago | Insider Cluster | $44.00 $47.34 | ▼ −7.59% | ▼ −4.32% | $5.04 (+88.55%) |
Jul 2, 2026 13w ago | Insider Cluster | $43.99 $46.78 | ▲ +6.34% | ▲ +6.76% | $5.04 (−88.54%) |
Jun 11, 2026 16w ago | Institutional Cluster | $36.05 $44.94 | ▲ +24.66% | ▲ +22.77% | $5.04 (−86.02%) |
May 30, 2026 17w ago | Insider Cluster | $40.90 $43.99 | ▲ +7.55% | ▲ +8.85% | $5.04 (−87.68%) |
May 29, 2026 17w ago | 144 | $40.90 $43.99 | ▼ −7.55% | ▼ −8.85% | $5.04 (+87.68%) |
May 12, 2026 20w ago | 8-K | $40.94 $34.03 | ▼ −16.88% | ▼ −15.15% | $5.04 (−87.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access